Donald Picker Sells Shares of MBRX
MBRX's Chief Science Officer sold shares valued at $65.52.
Key Points
- Donald Picker, Chief Science Officer at MBRX, sold 21 shares valued at $65.52 on June 22, 2026.
- MBRX shares traded near $2.93 on Thursday, with recent insider activities showing both buying and selling.
- Analyst HC Wainwright & Co. reiterated a buy rating for MBRX on March 24, 2026, with a target price of $22.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Donald Picker, the Chief Science Officer at MBRX, sold 21 shares of the company on June 22, 2026. The shares were sold at an average price of $3.12, bringing the total transaction value to $65.52. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Moleculin Biotech, Inc.
On the same day, Donald Picker also bought 71 shares, while Walter Klemp, the CEO and President, sold 360 shares. Jonathan Foster, the Chief Financial Officer, sold 41 shares at $3.12 each but also bought 174 shares. These transactions highlight a mix of buying and selling among MBRX's top executives.
Other Institutional Activity in MBRX
Several institutional investors have made moves in MBRX. Sabby Management, LLC opened a new position with 75,021 shares worth about $171,798. Geode Capital Management, LLC increased its holdings by 17,191 shares, resulting in a 113.6% increase, bringing their total to 32,329 shares valued at approximately $74,033. Rockefeller Capital Management L.P. also boosted its stake by 4,203 shares, a 1928% increase, ending with 4,421 shares worth about $10,124.
Analysts Set New Price Targets
On March 24, 2026, HC Wainwright & Co. reiterated its buy rating for MBRX with a price target of $22.00. The firm has consistently maintained a positive outlook on the stock. The consensus among analysts remains favorable, with a strong buy recommendation and a mean target price reflecting optimism about MBRX's prospects.
Bottom Line
Donald Picker's recent sale is part of a series of insider transactions at MBRX, reflecting diverse strategies among the company's leadership. Institutional investors also show varied interest, with some significantly increasing their stakes. Analysts maintain a positive stance on MBRX, suggesting confidence in its future performance. Keep in mind that insider trades are typically reported after they occur and may not indicate future moves.
Get Moleculin Biotech, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MBRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.